GSK faces mounting pressure from upcoming patent expirations despite recent pipeline activity, Citi analysts say. The U.K. drugmaker has launched ten pivotal trials, released data from five key studies, and completed two acquisitions this year. However, Citi cut its price target to 21 pounds from 22.50 pounds, arguing these moves still won't offset the patent cliff. GSK shares rose 1.3% to 18.81 pounds.

Novo Nordisk's Wegovy weight-loss pill is exceeding expectations, with first-quarter sales hitting 2.26 billion Danish kroner—nearly triple Bloomberg consensus, according to SB1 Markets analyst Johan Unnerus. The Danish pharma company confirmed the pill launch continues gaining momentum, with additional market expansions planned alongside an Ozempic diabetes pill for the U.S. and a high-dose Wegovy injectable version. Shares jumped 7.3%.

Jefferies analysts noted Novo Nordisk's full-year guidance was tweaked higher but remains at the top end of consensus, unlikely to trigger analyst upgrades. First-quarter adjusted sales came in 1% ahead of consensus, with GLP-1 treatments offsetting an insulin miss. Adjusted operating income beat expectations by 14%. Shares rose 7.4%.